The indie game Schedule I finds itself at the center of a copyright infringement controversy, but it's the accuser, Movie Games S.A., who's feeling the heat from fans. Dive into the details of this dispute and learn about the exciting updates Schedule I has in store.
Schedule I Recent Updates
Schedule I’s Copyright Infringement Accuser Gets Review Bombed on Steam
Schedule I, an innovative indie dope pushing simulator, has been hit with a copyright infringement claim by Movie Games S.A., creators of The Drug Dealer Simulator series. According to a report from the Polish Press Agency dated April 3, Movie Games S.A. alleges that Schedule I has infringed on their intellectual property by replicating elements such as plot, mechanics, and user interface.
Although no official outcomes have emerged from the ongoing investigation, the gaming community has taken sides, predominantly rallying behind Schedule I. As a result, The Drug Dealer Simulator and Drug Dealer Simulator 2 have been bombarded with negative reviews on Steam, earning the ratings of "Overwhelmingly Negative" and "Mostly Negative" respectively.
The backlash against Movie Games S.A. stems from accusations of bullying an indie developer and perceived hypocrisy, especially since similar games were not previously challenged. This has occurred despite the Drug Dealer Simulator series being hailed as a top criminal management game by both media and fans.
Schedule I is an engaging co-op crime simulation where players begin as small-time dealers and strive to ascend to the ranks of a kingpin. Launched in Early Access on PC on March 25, Schedule I has garnered "Overwhelmingly Positive" reviews on Steam and secured its position as the 2nd top-selling game on the platform, outperforming titles like inZOI, Monster Hunter Wilds, and R.E.P.O. According to SteamDB, Schedule I boasts an all-time peak of 459,075 concurrent players.
At Game8, we found Schedule I to be a captivating and rewarding experience, earning it the nickname "Breaking Bad" simulator. For a deeper dive into our impressions of Schedule I during its early access phase, check out our detailed review below!